RDY

Dr. Reddy's Laboratories Ltd. (RDY) | Rumor.io

Dr. Reddy's Laboratories

RDY

Attention (50-day avg)0%

Attention rank (50-day avg)#2,663

Bullish sentiment (50-day avg)21%

Price to earnings ratio29.2

Market capitalization10.4B

Earnings per share0.42

Dividend yield (TTM)2.65%

Revenue (annual)335.9B

Net income (annual)42.5B

Social

What share of all stock conversation is about RDY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% 0

May 20

Dr. Reddy's Laboratories Limited is mentioned in a list of stocks to buy, alongside other companies, with no specific reason given.
Hsbc has made a comment about Dr. Reddy's Laboratories Limited, but the content of the comment is not specified.
No other information about Dr. Reddy's Laboratories Limited is provided in the messages.

Generated by AI

Sentiment

Of the messages about RDY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	78.57% +74.32	88.49% -3.11
Bearish	—	—	21.43% -74.32	11.51% +3.11

Dec 10

With a market cap of only $29K, $RDY is a hidden gem waiting to be discovered, offering a low entry point with high growth potential.
The $RDY community is driven by a clear vision for the future, with features such as daily $SOL airdrops, merchandise sales to buy back tokens, and community-created profile pictures.
$RDY has shown significant growth potential in the past, with a previous jump from $25K to $75K in just 3 hours, indicating a strong possibility of future explosive gains.

Generated by AI

Topics

Of the messages about RDY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	57.14%	0.28%
Macro	—	—	42.86%	66.74%
Analysts	—	—	0%	21.01%
Controversies	—	—	0%	0.11%
Technical Analysis	—	—	0%	0.72%
Earnings	—	—	0%	11.15%

Earnings· Jul 26

Dr. Reddy's Laboratories Limited reports Q1 results with EPS of $0.40 and revenue of $543M, a 12.2% year-over-year increase.
The company's Q1 revenue growth outpaces the year-ago period, driven by a strong performance in various markets.
Dr. Reddy's Q1 EPS of $0.40 beats expectations, indicating a positive start to the year for the pharmaceutical company.

Analysts· Apr 23

Dr. Reddy's Labs (RDY) rose 8% as the Nifty Pharma index gained 2.36%, driven by the company's stock.
Cipla received USFDA approval for a generic Ventolin HFA, contributing to the pharma sector's performance.
Dr. Reddy's and Cipla were safe haven stocks during the market crash, while Auto and IT stocks hit 52-week lows.

Announcements· Jan 23

Dr. Reddy's Laboratories reported Q3 earnings with a $165 million net income and $977 million revenue, attributed to the acquired nicotine replacement business.
The company's Q3 revenue growth was driven by its global market gains, making it a solid story for long-term investors.
Dr. Reddy's Laboratories' Q3 earnings call transcript is available for investors to review, providing detailed information on the company's financial performance.

Macro· Apr 23

The Indian market experienced a crash, with Nifty falling 177 pts and Bank Nifty down 474 pts, led by the IT sector's 4% drop.
The pharma sector surged, with Dr. Reddy's Laboratories Limited's stock price rising by 6.6% and Cipla's by 3.3%, amidst the market downturn.
The global crude oil price crossed $100 due to Hormuz tensions, impacting the Indian market and contributing to the overall market decline.

Technical Analysis· Jan 25

$RDY is trading at or below its 200-day SMA, with a 13-day momentum indicator at -23.
The stock has a 6-day near-low, previous close low, and a 22-day accelerated moving average.
The median flight of $RDY is 121 million shares.

Generated by AI

Community

Of the messages about RDY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	27.27%	18.73%
Newcomers	—	100%	72.73%	81.27%

Regulars· Jul 27

Dr. Reddy's Laboratories Limited has filed form 6-K with the SEC, indicating recent company developments.
Credit Suisse has downgraded Dr. Reddy's to Neutral after the company's Q1 report, citing concerns over revenue growth.
Dr. Reddy's is expected to record its sharpest one-day loss in five years as a result of the downgraded rating by Credit Suisse.

Newcomers· May 20

New investors are looking at Dr. Reddy's Laboratories Limited as a potential stock to buy, considering its potential for growth alongside other companies in the same sector.
The recent commentary from Hsbc regarding Dr. Reddy's Laboratories Limited is being closely watched by newcomers, who are seeking to understand the impact of this opinion on the company's stock price.
Dr. Reddy's Laboratories Limited is being compared to other companies like Mankind Pharma and Zydus Life by newcomers, who are trying to determine which stock might be the better investment opportunity.

Generated by AI

News

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

12d agoReuters

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

Despite revenue decline and regulatory hurdles, Dr Reddy's Laboratories Ltd (RDY) focuses on strategic growth in emerging markets and innovation.

2mo agoYahoo Finance

RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories

2mo agoMorningstar

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

2mo agoMorningstar

Dr. Reddy’s Q1 FY2026 Interim Financials Cleared in Independent Review

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Goldman Sachs cuts Dr. Reddy’s stock price target on margin pressure

2mo agoInvesting.com

Also Discussed

Investors talking about RDY also mention

#	Name	Attention
1	HDFC Bank Ltd. ADRHDB	0%new
2	Steakholder Foods Ltd. ADRSTKH	0%0
3	Radware Ltd.RDWR	0%new
4	Phibro Animal Health Corporation Class A Common StockPAHC	0%0
5	Perrigo Company plcPRGO	0%0
6	BHIL - Benson Hill, Inc.	——
7	Elanco Animal Health IncELAN	0%new
8	OMIC - Singular Genomics Systems, Inc.	——
9	InterCure Ltd.INCR	0%new
10	Pacira BioSciences, Inc.PCRX	0%new

Dr. Reddy's Laboratories Ltd.

Healthcare
Drug Manufacturers - Specialty & Generic

Dr. Reddy’s Laboratories Ltd. ADR is a healthcare and pharmaceutical company that develops, manufactures, and markets a broad portfolio of medicines and related products. The company serves patients and healthcare providers through branded and generic prescription drugs, over-the-counter treatments, active pharmaceutical ingredients, and biosimilars. Its operations also include pharmaceutical services and contract manufacturing activities that support drug development and supply chains. Dr. Reddy’s Laboratories Ltd. ADR participates in therapeutic areas such as gastroenterology, cardiovascular care, diabetes, dermatology, oncology, respiratory medicine, and pain management. Headquartered in Hyderabad, India, the company plays an important role in the global generic medicines market and in the broader healthcare supply chain through its international commercial presence and diversified pharmaceutical offerings.

Website

Location

8-2-337, Road No. 3

Hyderabad, 500034

India

Social

What share of all stock conversation is about RDY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% 0

May 20

Dr. Reddy's Laboratories Limited is mentioned in a list of stocks to buy, alongside other companies, with no specific reason given.
Hsbc has made a comment about Dr. Reddy's Laboratories Limited, but the content of the comment is not specified.
No other information about Dr. Reddy's Laboratories Limited is provided in the messages.

Generated by AI

Sentiment

Of the messages about RDY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	78.57% +74.32	88.49% -3.11
Bearish	—	—	21.43% -74.32	11.51% +3.11

Dec 10

With a market cap of only $29K, $RDY is a hidden gem waiting to be discovered, offering a low entry point with high growth potential.
The $RDY community is driven by a clear vision for the future, with features such as daily $SOL airdrops, merchandise sales to buy back tokens, and community-created profile pictures.
$RDY has shown significant growth potential in the past, with a previous jump from $25K to $75K in just 3 hours, indicating a strong possibility of future explosive gains.

Generated by AI

Topics

Of the messages about RDY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	57.14%	0.28%
Macro	—	—	42.86%	66.74%
Analysts	—	—	0%	21.01%
Controversies	—	—	0%	0.11%
Technical Analysis	—	—	0%	0.72%
Earnings	—	—	0%	11.15%

Earnings· Jul 26

Dr. Reddy's Laboratories Limited reports Q1 results with EPS of $0.40 and revenue of $543M, a 12.2% year-over-year increase.
The company's Q1 revenue growth outpaces the year-ago period, driven by a strong performance in various markets.
Dr. Reddy's Q1 EPS of $0.40 beats expectations, indicating a positive start to the year for the pharmaceutical company.

Analysts· Apr 23

Dr. Reddy's Labs (RDY) rose 8% as the Nifty Pharma index gained 2.36%, driven by the company's stock.
Cipla received USFDA approval for a generic Ventolin HFA, contributing to the pharma sector's performance.
Dr. Reddy's and Cipla were safe haven stocks during the market crash, while Auto and IT stocks hit 52-week lows.

Announcements· Jan 23

Dr. Reddy's Laboratories reported Q3 earnings with a $165 million net income and $977 million revenue, attributed to the acquired nicotine replacement business.
The company's Q3 revenue growth was driven by its global market gains, making it a solid story for long-term investors.
Dr. Reddy's Laboratories' Q3 earnings call transcript is available for investors to review, providing detailed information on the company's financial performance.

Macro· Apr 23

The Indian market experienced a crash, with Nifty falling 177 pts and Bank Nifty down 474 pts, led by the IT sector's 4% drop.
The pharma sector surged, with Dr. Reddy's Laboratories Limited's stock price rising by 6.6% and Cipla's by 3.3%, amidst the market downturn.
The global crude oil price crossed $100 due to Hormuz tensions, impacting the Indian market and contributing to the overall market decline.

Technical Analysis· Jan 25

$RDY is trading at or below its 200-day SMA, with a 13-day momentum indicator at -23.
The stock has a 6-day near-low, previous close low, and a 22-day accelerated moving average.
The median flight of $RDY is 121 million shares.

Generated by AI

Community

Of the messages about RDY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	27.27%	18.73%
Newcomers	—	100%	72.73%	81.27%

Regulars· Jul 27

Dr. Reddy's Laboratories Limited has filed form 6-K with the SEC, indicating recent company developments.
Credit Suisse has downgraded Dr. Reddy's to Neutral after the company's Q1 report, citing concerns over revenue growth.
Dr. Reddy's is expected to record its sharpest one-day loss in five years as a result of the downgraded rating by Credit Suisse.

Newcomers· May 20

New investors are looking at Dr. Reddy's Laboratories Limited as a potential stock to buy, considering its potential for growth alongside other companies in the same sector.
The recent commentary from Hsbc regarding Dr. Reddy's Laboratories Limited is being closely watched by newcomers, who are seeking to understand the impact of this opinion on the company's stock price.
Dr. Reddy's Laboratories Limited is being compared to other companies like Mankind Pharma and Zydus Life by newcomers, who are trying to determine which stock might be the better investment opportunity.

Generated by AI

Dr. Reddy's Laboratories

Social

May 20

Dec 10

Earnings· Jul 26

Analysts· Apr 23

Announcements· Jan 23

Macro· Apr 23

Technical Analysis· Jan 25

Regulars· Jul 27

Newcomers· May 20

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

Dr. Reddy’s Q1 FY2026 Interim Financials Cleared in Independent Review

Goldman Sachs cuts Dr. Reddy’s stock price target on margin pressure

Also Discussed

Dr. Reddy's Laboratories Ltd.

Company Information

Location

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

Dr. Reddy’s Q1 FY2026 Interim Financials Cleared in Independent Review

Goldman Sachs cuts Dr. Reddy’s stock price target on margin pressure

Also Discussed

Social

May 20

Dec 10

Earnings· Jul 26

Analysts· Apr 23

Announcements· Jan 23

Macro· Apr 23

Technical Analysis· Jan 25

Regulars· Jul 27

Newcomers· May 20